Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02473250 · ClinicalTrials.gov registry record · Phase 4

Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging

A Phase 4 study of Bipolar Disorder, sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT02473250: Completed Phase 4 study of Bipolar Disorder, sponsored by New York State Psychiatric Institute.

NCT02473250 is a Phase 4 study of Bipolar Disorder that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 40 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02473250, a Phase 4 study of Bipolar Disorder, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This study is for subjects with a diagnosis of bipolar disorder who have depression at the time of recruitment. It involves brain imaging with an MRI (magnetic resonance imaging) and PET scan (positron emission tomography) and treatment with an antidepressant. The medication involves adding an SSRI (either celexa/citalopram or prozac/fluoxetine) to a mood stabilizer.

Primary Outcome

Depression severity. Minimum=0, Maximum=60. Higher numbers correspond to greater depression severity. The percent change between week 0 and the last observation was calculated.

Conditions Studied

Interventions

  • DRUG Fluoxetine
  • DRUG Citalopram

Study Locations (1)

New York

  • New York State Psychiatric Institute/Columbia University Medical Center - New York

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2015-01
Est. Completion 2019-12
Phase Phase 4

What the finished NCT02473250 record still lists

NCT02473250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which Fluoxetine is the first listed.

NCT02473250 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT02473250 about?

NCT02473250 is a clinical study titled "Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging". This study is for subjects with a diagnosis of bipolar disorder who have depression at the time of recruitment. It involves brain imaging with an MRI (magnetic resonance imaging) and PET scan (positron emission tomography) and treatment with an antidepressant. The medication involves adding an SSRI ...

What is the current status of trial NCT02473250?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2015-01. Estimated completion is 2019-12.

What conditions does trial NCT02473250 study?

This clinical trial studies the following conditions: Bipolar Disorder.

What interventions are being tested in trial NCT02473250?

The interventions under investigation include: Fluoxetine (DRUG), Citalopram (DRUG).

Who is sponsoring clinical trial NCT02473250?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02473250 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bipolar Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02473250's enrollment target sits among peer trials

40 123rd of 162 higher than 36 of 162 other Bipolar Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bipolar Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02473250, the US trial registry maintained by the National Library of Medicine. NCT02473250 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.